Farshid Dayyani

机构：University of California, Irvine, University of California, Irvine Medical Center, UC Irvine Health, UC Irvine Chao Family Comprehensive Cancer Center · ORCID：0000-0002-4970-5189

发表论文 308 篇 · 总被引 8047 次 · h-index 38

代表论文

• Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer (2026 · Journal for ImmunoTherapy of Cancer · 被引 9)
• Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers (2026 · Cancer · 被引 5)
• Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315) (2026 · The Oncologist · 被引 2)
• Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: Primary results from the phase IIIb TOURMALINE study (2026 · Journal of Hepatology · 被引 1)
• Real-world evidence for the impact of circadian clock on the benefit from immune checkpoint inhibitors in solid tumors (2026 · BMC Cancer · 被引 1)
• Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial (2026 · Future Oncology · 被引 1)